Cargando…
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab rav...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225632/ https://www.ncbi.nlm.nih.gov/pubmed/28077160 http://dx.doi.org/10.1186/s13045-016-0380-0 |